Pila Competitors

Stocks . Sweden . 
Stock . Pila Pharma AB
PILA Stock   2.06  0.08  3.74%   
Pila Pharma AB competes with NextCell Pharma, Biovica International, Sprint Bioscience, Nanologica, and Spago Nanomedical; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Pila Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Pila Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Pila Pharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Pila Pharma competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
0.102.065.03
Details
Intrinsic
Valuation
LowRealHigh
0.112.155.12
Details
Naive
Forecast
LowNextHigh
0.042.085.06
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.072.262.44
Details

Pila Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pila Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Pila and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pila Pharma AB does not affect the price movement of the other competitor.

High positive correlations

ATORX
+ 0.97
ACTI
ICO
+ 0.95
NXTCL
LXB
+ 0.92
NICA
ICO
+ 0.91
ATORX
ATORX
+ 0.87
NXTCL
ICO
+ 0.87
ACTI
  

High negative correlations

ICO
- 0.86
SPRINT
NICA
- 0.86
SPRINT
SPRINT
- 0.83
NXTCL
LXB
- 0.77
SPRINT
LXB
- 0.72
ONCOZ
ONCOZ
- 0.71
NICA

Risk-Adjusted Indicators

There is a big difference between Pila Stock performing well and Pila Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pila Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NXTCL  2.46 (0.39) 0.00 (3.62) 0.00 
 0.00 
 5.80 
(5.38)
 20.33 
ACTI  4.26 (1.78) 0.00 (0.83) 0.00 
 0.00 
 7.24 
(11.08)
 47.54 
BIOVIC-B  2.85 (0.60) 0.00 (2.94) 0.00 
 0.00 
 7.55 
(5.17)
 46.51 
SPRINT  4.83  1.98  0.58  0.89  2.06 
(7.54)
 7.46 
(4.48)
 118.70 
NICA  3.21 (0.58) 0.00  11.31  0.00 
 0.00 
 6.19 
(6.93)
 25.12 
SPAGO  6.49  0.11  0.00  0.01  0.00 
 0.00 
 10.00 
(12.00)
 119.12 
ATORX  7.54 (3.25) 0.00  1.40  0.00 
 0.00 
 10.81 
(22.93)
 55.76 
ONCOZ  3.41  0.26  0.04 (0.21) 3.56 
(4.24)
 9.53 
(6.62)
 17.50 
ICO  2.15 (1.00) 0.00 (1.39) 0.00 
 0.00 
 3.36 
(6.16)
 10.87 
LXB  3.58 (0.52) 0.00 (1.29) 0.00 
 0.00 
 10.14 
(8.16)
 26.03 
All Fundamental Data

Pila Pharma Competitive Analysis

The better you understand Pila Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pila Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pila Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PILA NXTCL ACTI BIOVIC-B SPRINT NICA SPAGO ATORX ONCOZ ICO
 3.74 
 2.06 
Pila
 5.80 
 0.73 
NextCell
 7.26 
 0.05 
Active
 8.82 
 0.37 
Biovica
 0.68 
 1.47 
Sprint
 1.30 
 0.78 
Nanologica
 29.03 
 0.12 
Spago
 0.00 
 0.34 
Alligator
 0.45 
 6.76 
Oncozenge
 3.64 
 1.14 
Iconovo
Market Volatility
(90 Days Market Risk)
Risky
Extremely Dangerous
Out of control
Out of control
Out of control
Extremely Dangerous
Out of control
Out of control
Relatively risky
Dangerous
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Fair
Weakest
Weakest
Weakest
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
High
Fair
Low
Small
High
High
Low
Moderate
High
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
42.29
1.37
2.56
2.69
N/A
11.08
9.65
N/A
7.93
Net Asset
31.81 M
124.66 M
56.8 M
151.63 M
79.14 M
98.32 M
191.62 M
333.2 M
85.23 M
148.54 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-1.18
EBITDA
(17.16 M)
(34.08 M)
(48.52 M)
(75.36 M)
(24.22 M)
(31.13 M)
(38.7 M)
(130.36 M)
(4.89 M)
(20.45 M)
Operating Margin
-4.58
-4.75
N/A
-14.77
-76.0
-8.35
-6.11
-5.39
N/A
-1.2
Current Valuation
48.17 M
134.94 M
224.92 M
175.91 M
24.98 M
436.11 M
(13.94 M)
236.82 M
22.93 M
417.92 M
Price To Book
7.07
2.01
5.63
2.26
2.61
44.5
0.28
2.57
1.67
4.25
Current Asset
N/A
N/A
65 M
N/A
25 M
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
N/A
(39 M)
N/A
N/A
N/A
N/A
N/A
Beta
N/A
0.43
0.53
1.02
1.32
1.25
1.87
1.12
1.22
0.53
Number Of Employees
3
15
9
27
34
6
15
53
2
31
Shares Outstanding
18.41 M
34.38 M
264.89 M
39.47 M
69.8 M
36.15 M
90.94 M
220.58 M
11.71 M
8.85 M
Cash Flow From Operations
(9.36 M)
(33.31 M)
(46.17 M)
(52.13 M)
(40.12 M)
(46.49 M)
(35.57 M)
(127.03 M)
(4.77 M)
(11.01 M)
Total Debt
N/A
N/A
200 K
8.78 M
N/A
1.33 M
N/A
3.51 M
N/A
N/A
Return On Equity
-1.3
-0.3
-1.44
-0.65
-1.09
-0.89
-0.21
-1.04
N/A
-0.32
Z Score
N/A
N/A
N/A
27.0
N/A
N/A
N/A
73.2
N/A
N/A
Return On Asset
-0.27
-0.17
-0.67
-0.36
-0.59
-0.25
-0.12
-0.48
N/A
-0.17
Book Value Per Share
0.47
3.1
0.13
2.86
0.63
2.05
2.17
0.4
3.26
11.96
Current Liabilities
N/A
N/A
29 M
N/A
21 M
N/A
N/A
N/A
N/A
N/A
Total Asset
31.81 M
124.66 M
56.8 M
151.63 M
79.14 M
98.32 M
191.62 M
333.2 M
85.23 M
148.54 M
Target Price
7.32
N/A
3.0
22.6
32.0
15.0
4.8
3.77
2.5
105.0
Debt To Equity
N/A
N/A
268.1
N/A
32.2
N/A
N/A
5.1
N/A
N/A
Shares Owned By Institutions
N/A
5.27
15.84
3.73
2.59
10.33
N/A
11.58
1.47
30.94
Market Capitalization
50.44 M
255.91 M
268.37 M
403.5 M
53.17 M
367.95 M
72.75 M
431.05 M
69.46 M
389.29 M
Price To Earning
N/A
N/A
-8.47
N/A
32.79
N/A
N/A
N/A
N/A
N/A
Price To Sales
25.21
37.14
29.72
48.31
27.09
87.4
9.48
17.76
N/A
13.36
Net Income
(17.21 M)
(35.02 M)
(49.83 M)
(60 M)
(25.08 M)
(44.83 M)
(39.07 M)
(141.74 M)
(3.89 M)
(26.16 M)
Earnings Per Share
-1.72
-0.8
-0.25
-2.11
-0.75
-1.88
-1.04
-0.6
-3.27
-3.31
Shares Owned By Insiders
43.03
42.82
45.94
N/A
35.31
61.81
25.78
51.92
51.58
47.95
Revenue
719.23 K
5.59 M
N/A
2.04 M
35.11 M
12.91 M
660 K
12.94 M
N/A
15.41 M
Working Capital
N/A
N/A
36 M
N/A
4 M
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
150.75 M
53.13 M
89.79 M
13.82 M
N/A
76.87 M
278.15 M
56.96 M
94.94 M
Cash Per Share
N/A
4.39
0.11
0.71
1.19
N/A
1.87
4.27
4.86
6.84
Gross Profit
680.94 K
(2.49 M)
6.72 M
4.73 M
24.59 M
3.5 M
(13.89 M)
(111.72 M)
N/A
21.31 M
Day Typical Price
2.08
0.71
0.0443
0.36
1.47
0.79
0.11
0.33
6.71
1.13
Accumulation Distribution
0.0783
0.0685
0.15
0.13
0.04
0.12
0.22
0.0882
0.0525
0.0351
Market Facilitation Index
0.17
0.05
0.007
0.05
0.06
0.1
0.026
0.03
0.36
0.04
Daily Balance Of Power
(0.47)
0.8
(0.51)
0.6
(0.17)
0.1
1.038462
N/A
0.0833
1.0
Period Momentum Indicator
(0.08)
0.04
(0)
0.03
(0.01)
0.01
0.027
N/A
0.03
0.04
Rate Of Daily Change
0.96
1.06
0.93
1.09
0.99
1.01
1.29
1.0
1.0
1.04
Day Median Price
2.09
0.71
0.0435
0.36
1.47
0.79
0.11
0.33
6.68
1.12
Price Action Indicator
(0.07)
0.045
7.0E-4
0.03
(0.01)
(0.01)
0.0265
0.015
0.095
0.04
Coefficient Of Variation
(3,570)
(950.48)
(420.69)
(939.59)
690.67
(753.94)
(52,636)
(329.80)
2005.39
(293.91)
Mean Deviation
2.4
2.46
4.26
2.85
4.83
3.21
6.49
7.54
3.41
2.15
Jensen Alpha
(0.13)
(0.39)
(1.78)
(0.60)
1.98
(0.58)
0.1143
(3.25)
0.2635
(1.00)
Total Risk Alpha
(0.31)
(0.62)
(2.16)
(0.97)
1.1
(0.88)
(1.01)
(4.13)
(0.1)
(1.15)
Sortino Ratio
N/A
N/A
N/A
N/A
0.5847
N/A
N/A
N/A
0.0441
N/A
Downside Variance
N/A
N/A
N/A
N/A
12.28
N/A
N/A
N/A
13.98
N/A
Standard Deviation
3.1
3.52
7.01
5.45
14.55
4.31
14.17
11.08
4.48
2.8
Kurtosis
0.6003
4.77
14.62
25.09
57.79
1.19
30.41
3.55
0.5827
0.5192
Potential Upside
5.5
5.8
7.24
7.55
7.46
6.19
10.0
10.81
9.53
3.36
Treynor Ratio
(0.13)
(3.62)
(0.83)
(2.94)
0.8891
11.31
0.0119
1.4
(0.21)
(1.39)
Maximum Drawdown
14.99
20.33
47.54
46.51
118.7
25.12
119.12
55.76
17.5
10.87
Variance
9.61
12.39
49.2
29.74
211.84
18.57
200.7
122.7
20.09
7.82
Market Risk Adjusted Performance
(0.12)
(3.61)
(0.82)
(2.93)
0.8991
11.32
0.0219
1.41
(0.20)
(1.38)
Risk Adjusted Performance
(0.01)
(0.07)
(0.16)
(0.07)
0.1117
(0.09)
0.0082
(0.20)
0.0436
(0.23)
Skewness
0.762
1.47
(2.91)
(3.69)
7.38
0.3034
4.63
(0.88)
0.5951
(0.70)
Semi Deviation
N/A
N/A
N/A
N/A
2.06
N/A
N/A
N/A
3.56
N/A
Information Ratio
(0.05)
(0.12)
(0.25)
(0.12)
0.1408
(0.15)
(0.01)
(0.31)
0.0368
(0.36)
Value At Risk
(4.53)
(5.38)
(11.08)
(5.17)
(4.48)
(6.93)
(12.00)
(22.93)
(6.62)
(6.16)
Expected Short fall
N/A
N/A
N/A
N/A
(7.54)
N/A
N/A
N/A
(4.24)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
3.5
N/A
N/A
N/A
3.74
N/A
Semi Variance
N/A
N/A
N/A
N/A
4.24
N/A
N/A
N/A
12.64
N/A

Pila Pharma Competition Performance Charts

Five steps to successful analysis of Pila Pharma Competition

Pila Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pila Pharma AB in relation to its competition. Pila Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Pila Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pila Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pila Pharma AB, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Pila Pharma position

In addition to having Pila Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wireless Thematic Idea Now

Wireless
Wireless Theme
Companies providing wireless technology and communication services. The Wireless theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pila Stock Analysis

When running Pila Pharma's price analysis, check to measure Pila Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pila Pharma is operating at the current time. Most of Pila Pharma's value examination focuses on studying past and present price action to predict the probability of Pila Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pila Pharma's price. Additionally, you may evaluate how the addition of Pila Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY